IBPA a mutual prodrug of ibuprofen and acetaminophen alleviates inflammation, immune dysregulation and fibrosis in preclinical models of systemic sclerosis.

Autoimmunity Fibrosis Inflammation Mutual prodrug Paracetamol Treatment

Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
03 Jun 2024
Historique:
received: 03 04 2024
revised: 20 05 2024
accepted: 23 05 2024
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 4 6 2024
Statut: aheadofprint

Résumé

Systemic sclerosis (SSc) is a devastating autoimmune illness with a wide range of clinical symptoms, including vascular abnormalities, inflammation, and persistent and progressive fibrosis. The disease's complicated pathophysiology makes it difficult to develop effective therapies, necessitating research into novel therapeutic options. Molecular hybridization is a strategy that can be used to develop new drugs that act on two or multiple targets and represents an interesting option to be explored for the treatment of complex diseases. We aimed to evaluate the effects of a hybrid mutual prodrug of ibuprofen and acetaminophen (IBPA) in peripheral blood mononuclear cells (PBMC) isolated from SSc patients, and in an in vivo model of SSc induced in BALB/c mice by intradermal injections of hypochlorous acid (HOCl) for 6 weeks. The mice were treated at the same time with daily intraperitoneal injections of IBPA (40 mg/kg). Pulmonary and skin fibrosis as well as immune responses were evaluated. IBPA significantly decreased the release of cytokines in PBMC culture supernatants from SSc patients after stimulation with phytohemagglutinin-M (IL-2, IL-4, IL-6, IL-10, IL-13, IL-17A, TNF and IFN-γ).In HOCl-induced SSc, IBPA treatment prevented dermal and pulmonary fibrosis, in addition to reducing CD4 + T and B cells activation and reversing the M2 polarization of macrophages in spleen cells, and inhibiting IFN-γ secretion in splenocyte cultures. These results show the anti-inflammatory and antifibrotic effects of IBPA in SSc and highlight the therapeutic potential of this mutual prodrug, providing support for future studies.

Identifiants

pubmed: 38833846
pii: S1567-5769(24)00864-6
doi: 10.1016/j.intimp.2024.112344
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112344

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anderson Rodrigues de Almeida (A)

Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife, PE, Brazil; Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Francisco Jaime Bezerra Mendonça Junior (F)

Laboratório de Síntese e Vetorização de Moléculas, Departamento de Ciências Biológicas, Centro de Ciências Biológicas e Sociais Aplicadas, Universidade Estadual da Paraíba, João Pessoa, PB, Brazil.

Andréa Tavares Dantas (A)

Serviço de Reumatologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Maria Eduarda de Oliveira Gonçalves (M)

Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Charlotte Chêne (C)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Mohamed Jeljeli (M)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Sandrine Chouzenoux (S)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Marine Thomas (M)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Lílian David de Azevedo Valadares (L)

Serviço de Reumatologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Maria Andreza Bezerra Correia (M)

Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Widarlane Ângela da Silva Alves (W)

Departamento de Fisiologia e Farmacologia, Centro de Biociências, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Eduardo Carvalho Lira (E)

Departamento de Fisiologia e Farmacologia, Centro de Biociências, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Ludivine Doridot (L)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Moacyr Jesus Barreto de Melo Rêgo (M)

Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Michelly Cristiny Pereira (M)

Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife, PE, Brazil; Departamento de Fisiologia e Farmacologia, Centro de Biociências, Universidade Federal de Pernambuco, Recife, PE, Brazil. Electronic address: michelly.pereira@ufpe.br.

Angela Luzia Branco Pinto Duarte (A)

Serviço de Reumatologia, Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Dulcineia Saes Parra Abdalla (D)

Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, SP, Brazil.

Carole Nicco (C)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Frédéric Batteux (F)

Université Paris Cité, Institut Cochin, Inserm, CNRS, Paris, France.

Maira Galdino da Rocha Pitta (M)

Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Recife, PE, Brazil.

Classifications MeSH